Aziyo Biologics, INC.: insider trades · United States · SEC (Form 4)

About Aziyo Biologics, INC.

Aziyo Biologics, Inc. is a U.S.-listed healthcare / medtech company historically quoted on Nasdaq under the ticker AZYO in the United States. The company is based in Silver Spring, Maryland, and was built around a differentiated thesis: using biological tissue to improve the compatibility between implantable medical devices and the patients who receive them. From an equity research perspective, Aziyo has long sat at the intersection of regenerative medicine, biomaterials and surgical care, with a commercial model that relies on healthcare providers, surgeons and selected strategic partners. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708527/000155837022003073/azyo-20211231x10k.htm?utm_source=openai)) Its business is organized around a portfolio of biologic products derived from human and porcine tissue. These products serve several end markets, including implantable electronic devices and cardiovascular procedures, orthopedic and spine repair, and soft-tissue reconstruction. Aziyo’s core franchises have included biologic envelopes and tissue-based reconstruction products designed to support healing, reduce complications and improve device-tissue integration. In addition, the company has had non-core and contract manufacturing activities, which broaden its commercial footprint beyond the main branded product set. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708527/000155837022003073/azyo-20211231x10k.htm?utm_source=openai)) Competitive positioning is anchored in specialization. Rather than competing as a broad-based medical device platform, Aziyo has focused on niche regenerative solutions where clinical evidence, regulatory status and distribution partnerships matter materially. That focus gives the company exposure to higher-value, technically demanding markets, but it also means execution risk is elevated: product adoption depends on surgeon acceptance, reimbursement dynamics, regulatory milestones and the ability to scale through partners. The company has highlighted collaborations with Medtronic, Sientra and LeMaitre Vascular, underscoring a go-to-market strategy that combines proprietary development with established commercial channels. ([investors.aziyo.com](https://investors.aziyo.com/news-releases/news-release-details/aziyo-biologicsr-announces-exclusive-agreement-medtronicr?utm_source=openai)) Recent milestones have centered on CanGaroo RM, a next-generation antibacterial biomaterial envelope for implantable electronic devices. In 2022 and 2023, Aziyo described regulatory progress, product-development updates and commercial traction in certain business units. At the same time, the company also disclosed a voluntary recall of some viable bone matrix products in July 2023, a reminder that product-quality and manufacturing execution are key watchpoints in this segment. In September 2023, Aziyo announced a rebrand to Elutia as part of a strategic shift toward drug-eluting biomatrices, which is important context for investors monitoring SEC Form 4 filings and the company’s evolution. Overall, the name AZYO represents a small-cap, highly specialized U.S. healthcare story with meaningful upside potential, but also clear regulatory, operational and commercial risk. ([investors.aziyo.com](https://investors.aziyo.com/news-releases/news-release-details/aziyo-announces-fda-510k-submission-cangaroor-rm-its-next?utm_source=openai))